What isMOTS-cFDA Status, Evidence and Risks (2026)

What MOTS-c is

MOTS-c is a peptide of 16 amino acids. It is encoded in mitochondrial DNA, inside the gene for a piece of the mitochondria's own machinery (the 12S rRNA) ².

Mitochondria are the parts of a cell that turn food into usable energy. They carry a small genome of their own. MOTS-c was first described in 2015 ³.

It belongs to a small group called mitochondrial-derived peptides, and it is studied mainly for metabolism: how the body handles sugar and fat ^3,4.

Where FDA stands

1. Apr 2026: FDA took MOTS-c and 11 other peptides off Category 2 after their nominators withdrew them ^1,5. That approved nothing.
2. Jul 23, 2026: FDA staff told its compounding advisory committee it was "proposing that MOTS-c (free base) and MOTS-c acetate NOT be included on the 503A Bulks List" ². The committee voted 7 to 5, with 2 abstentions, to recommend it anyway ^6,7.
3. Oct 28, 2026: HHS filed an interim policy saying it won't take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound MOTS-c acetate, under the skin or into muscle, when the policy's conditions are met ^8,9. It publishes in the Federal Register Oct 30, 2026 ⁸.
4. Today: not on the 503A bulks list, not approved by FDA for any use.

The vote is advice. FDA makes the decision, and adding a substance to the 503A bulks list takes notice-and-comment rulemaking ⁶. Are peptides legal? explains what each list means.

The HHS policy is interim and not binding. It lasts while the 503A list goes through rulemaking, and HHS can revisit it if a safety or quality problem shows up ⁸. It approves nothing. Its list names MOTS-c acetate. FDA's review also covered MOTS-c free base ^2,8. Read the full breakdown in HHS's Oct 28 peptide policy. The FDA Peptide Tracker logs each step.

What the research shows

Animal and cell studies (preclinical). In mice, MOTS-c suppressed diet-induced obesity and insulin resistance tied to diet and age ^2,3. FDA describes the research as "limited to in-vitro models and small rodent models" ². The benefits quoted online, from weight to endurance, trace back to this work.

Human studies (observations only). Researchers have measured MOTS-c levels in people's blood and muscle. A 2023 review collected findings like these ⁴:

• Levels were lower in obese boys and adolescents, tied to insulin resistance, but not in obese girls.
• Levels were low in type 2 diabetes and tracked with HbA1c, a long-term blood sugar marker.
• Levels appear to fall with age, in muscle and in blood.
• Endurance exercise did not change blood levels in healthy people or in women with PCOS in the studies reviewed.

These are associations. They do not show what taking it does.

Human treatment trials. FDA did not identify publicly available clinical studies giving pharmacokinetic data for MOTS-c, and it has "not identified any human exposure data" for MOTS-c drug products by any route ^1,2. We found no published trial of MOTS-c as a treatment in people.

Known risks and FDA's concerns

FDA's stated concerns, from its Category 2 page ¹:

• Immune reactions. MOTS-c "may pose significant risk for immunogenicity for certain routes of administration."
• Impurities. "Complexities with regard to peptide-related impurities and API characterization."
• No human data. FDA "lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans."

From FDA's Jul 2026 presentation ²:

• Immunogenicity is a particular concern for injection, the route proposed for compounding.
• There is a "lack of clinical and nonclinical safety information."
• In a lab test with human whole blood, MOTS-c underwent "rapid proteolytic hydrolysis," meaning it broke down quickly into shorter pieces.

No reliable side effect list exists, because no one has published a human treatment trial to record one.

Why it's sold online anyway

MOTS-c is easy to buy from sites that label it "research use only" or "not for human consumption." That label is the seller saying the product is not for people.

No prescriber reviews your health history. No licensed pharmacy compounds it for one patient or checks it for human use.

The panel vote did not change any of that. Prescription vs Research Peptides has more.

On the same shelf: Epitalon, which the panel also voted for in Jul 2026. For another peptide in the same vote, see BPC-157.

Asked a lot.

The sources.

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
2. FDA. Pharmacy Compounding Advisory Committee, Jul 23, 2026, FDA presentations (MOTS-c). Read it
3. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. Read it
4. Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21:36. Read it
5. Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
6. Bass Berry. FDA Advisory Committee Recommends Six Peptides for Compounding (Jul 31, 2026). Read it
7. AJMC. FDA Panel Backs 6 Peptides for Compounding (Jul 31, 2026). Read it
8. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
9. Hyman, Phelps and McNamara, FDA Law Blog. The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line (Oct 28, 2026). Read it